March 11, 2019. Cellect Biotechnology, a developer of a novel stem cell production technology, today announced positive preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells. Results of this third-party study further validate that Cellect’s Apograft™ technology significantly improves both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells originating from bone marrow, peripheral blood, umbilical cord, and adipose tissue.
Preliminary Results Include:
- Higher degree of stemness (both in Cell2in and standard assays) maintained through repeated expansions of bone marrow and umbilical cord derived mesenchymal stem cells
- Improved expansion of adipose derived mesenchymal stem cells in early and late passages
- Significantly increased stemness of hematopoietic stem cells within two hours of the ApoGraft™ process
According to the company CEO, “The data, which has now been validated through a third-party corporate collaboration, demonstrates that Cellect’s ApoGraft™ technology enables improved quality stem cell production at a lower cost by providing a platform technology aimed at benefiting multiple stem cell therapy products,” commented Shai Yarkoni, Cellect’s Chief Executive Officer. “Together with our clinical data of allogeneic bone HSC (bone marrow) transplantation, this new program further supports the significance of the ApoGraft™ technology to all allogenic cell therapy. This is particularly relevant for MSCs, where the industry is moving towards off-the-shelf therapies requiring much larger expansions and represents a sizeable market opportunity for Cellect.”
About
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. Cellect Biotechnology Ltd. has a collaboration with the Washington University in determining the safety and tolerability in Phase I/II study using ApoGraft for bone marrow transplantations in the United States. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.
Financial data
Third Quarter 2018 Financial Results:
Research and development (R&D) expenses for the third quarter of 2018 were $1.13 million, compared to $0.69 million in the second quarter of 2018 and $0.79 million in the third quarter of 2017. The increase in the third quarter of 2018 as compared to the second quarter of 2018 was primarily due to increased expenses related to the Company’s ongoing clinical trial and product development expenses.
General and administrative (G&A) expenses for the third quarter of 2018 were $1.08 million, compared to $1.00 million in the second quarter of 2018 and $0.96 million in the third quarter of 2017. The change in the third quarter of 2018 as compared to the second quarter of 2018 mainly derived from an increase in expenses related to business development in the third quarter of 2018, offset by a decrease in costs of share-based compensation.
Financial income for the third quarter of 2018 was $0.35 million, compared to financial income of $0.03 million in the second quarter of 2018. The increase was primarily due to changes related to fair value of the tradable and non-tradable warrants issued in prior fundraisings.
Net loss for the third quarter of 2018 was $1.9 million, or $0.014 per share and $0.29 per ADS, compared to $1.6 million, or $0.013 per share and $0.25 per ADS, in the second quarter of 2018, and $2.2 million, or $0.019 per share and $0.39 per ADS, in the third quarter of 2017.
Balance Sheet Highlights:
Cash and cash equivalents and marketable securities totaled $6.45 million as of September 30, 2018, compared to $8.26 million on June 30, 2018, and $7.6 million on December 31, 2017. The change in the cash and cash equivalents and marketable securities was primarily due to net proceeds of $3.5 million from a registered direct offering completed in January 2018, offset by cash used in operations during the period.
Shareholders’ equity totaled $4.5 million as of September 30, 2018, compared to $6.1 million on June 30, 2018, and $5.2 million on December 31, 2017.
Stock influences and Risk factors
Continued affirmation of the company’s stem cell process could be a catalyst for the company shares.
Competition in the biotech sector is strong and the company may lose forward momentum if a competitor has better research.
The company relies on funding from public offering that may dilute the value of the shares.
Stock chart
On Monday, March 11, 2019, APOP shares were at $1.23 on traded volume of 5.4 million shares. The current RSI (14) is 43.63
At $1.23, APOP shares are trading below their 50 DMA and 200 DMA of $1.94 and $4.50 respectively.
Traders News Source recent picks and track record can be viewed here – https://tradersnewssource.com/traders-news-source-new-members/
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Mark Roberts. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
